Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

por Reck, Martin, Rodríguez-Abreu, Delvys, Robinson, Andrew G., Hui, Rina, Csőszi, Tibor, Fülöp, Andrea, Gottfried, Maya, Peled, Nir, Tafreshi, Ali, Cuffe, Sinead, O'Brien, Mary, Rao, Suman, Hotta, Katsuyuki, Leal, Ticiana A., Riess, Jonathan W., Jensen, Erin, Zhao, Bin, Pietanza, M. Catherine, Brahmer, Julie R.
Publicado 2021

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Stud...

por Trukhin, Dmytro, Poddubskaya, Elena, Andric, Zoran, Makharadze, Tamta, Bellala, Ravi Shankar, Charoentum, Chaiyut, Yañez Ruiz, Eduardo P., Fulop, Andrea, Hyder Ali, Irfhan Ali, Syrigos, Kostas, Katgi, Nuran, Lopez Chuken, Yamil Alonso, Rumyana, Ilieva, Reyes-Igama, Jasmin, Costamilan, Rita de Cassia, Del Campo García, Ana, Florez, Amalia, Paravisini, Alexandra, Millan, Susana
Publicado 2021